MedTrace Logo

Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma

NCT00301873 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2013-02-18

Study results available
· View outcomes & findings →

Summary

RATIONALE: Zoledronate may prevent bone loss in patients with primary malignant glioma.

PURPOSE: This phase II trial is studying how well zoledronate works in preventing osteoporosis in patients with primary malignant glioma.

Conditions

Interventions

DRUG

IV Zometa

Zometa will be given at 4 mg intravenously over 15 minutes every 3 months for 1 year.

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • Duke University

    lead OTHER

Principal Investigators

  • James J. Vredenburgh, MD · Duke University

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2011-02-28
Completion
2012-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00301873 on ClinicalTrials.gov